Show
{{imgMenuList.length - 9}} more figuresHide {{imgMenuList.length -
9}} figures
Show
{{tableMenuList.length - 5}} more tablesHide
{{tableMenuList.length - 5}} tables
Outline
Show full
outline
Hide outline
Show
{{imgMenuList.length - 9}} more figuresHide {{imgMenuList.length -
9}} figures
Show
{{tableMenuList.length - 5}} more tablesHide
{{tableMenuList.length - 5}} tables
Review Article|Open Access |Online First
Artificial intelligence in gut-brain axis research for Alzheimer’s disease: From associative insights toward causal inference and personalized interventions
Biomedical Innovation Center, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China
Beijing Key Laboratory for Therapeutic Cancer Vaccines, Beijing 100038, China
Department of Systems Neuropharmacology, Research Institute of Environmental Medicine, Nagoya University, Nagoya 464-8601, Japan
Department of Physiology, Faculty of Medicine, University of Toronto, Toronto M5S 1A8, Canada
The Institute of Basic Theory of Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China
Department of Pharmacy, Peking University People’s Hospital, Beijing 100044, China
College of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China
Hunan Engineering Technology Center of Standardization and Function of Chinese Herbal Decoction Pieces, Changsha 410208, China
Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
National International Joint Research Center for Molecular Chinese Medicine, Shanxi University of Chinese Medicine, Taiyuan 030024, China
† Yan Gao, Can Zhang, and Zhi-Wen Zhou contributed equally to this work.
Show Author Information
Hide Author Information
Highlights
(1) Discusses the potential and pitfalls of AI for causal inference in gut microbiota-AD research.
(2) Explores multi-modal fusion networks as a tool to map the gut-brain axis, emphasizing the need for experimental validation.
(3) Proposes a research agenda for developing digital twin models, moving from population-level associations toward personalized intervention strategies.
Abstract
Alzheimer’s disease (AD) research is shifting from a “brain-centered” model toward a “gut-brain axis system” perspective. However, the causal roles of gut microbiota in AD pathology remain elusive, as traditional association studies struggle to distinguish potential drivers from passengers. This review examines the potential applications and inherent limitations of artificial intelligence (AI) in dissecting this complex relationship. We discuss three emerging and conceptually promising directions: First, AI-frameworks for hypothesis-generating causal discovery that can prioritize microbiota-AD relationships for subsequent experimental validation, while recognizing that current approaches predominantly identify statistical associations rather than empirically supported causal conclusions; second, multi-modal fusion networks, when applied with appropriate regularization and validation, can assist in constructing cross-scale molecular maps across microbiota, metabolites, and the brain, though such pathway inferences require careful interpretation as they represent statistical associations rather than biochemically validated mechanisms; and third, the conceptual application of digital twin-based simulation as a long-term vision for personalized microbiota modulation, which currently lacks the ecological resolution and validation required for predictive modeling. By integrating multi-pathway mechanisms of the gut-brain axis and characteristic profiles of gut microbiota, we critically evaluate the technical advantages of machine learning in microbiome data analysis alongside major challenges including overfitting, batch effects, confounding factors, and reproducibility. Leveraging AI-driven microbiota analysis, we propose a phased translational roadmap, from near-term standardization and cross-cohort validation, through mid-term endophenotyping and trial enrichment strategies, to the long-term exploration of personalized interventions, toward the eventual goal of precision prevention. This article outlines a full-cycle framework from discovery to clinical translation and envisions a conceptual ecosystem for future intelligent microecological health management. Achieving the promise of AI-empowered gut-brain axis research will require deep integration across neuroscience, microbiology, computational science, and clinical medicine, alongside rigorous experimental validation, standardized protocols, and realistic appraisal of current technological boundaries.
Graphical Abstract
This graphical abstract illustrates an intelligent microecological health management framework for Alzheimer's disease. It integrates gut brain axis mechanisms with multi omic artificial intelligence analysis. The workflow begins with discovery of associations between microbiota and Alzheimer's disease. It then advances to modeling through causal discovery and multi model fusion. The final stage focuses on translation into precision prevention and personalized intervention. Experimental validation is required before any causal conclusion can be drawn. The framework spans four disciplines including neuroscience microbiology computational science and clinical medicine. This integrated approach moves from associative insights toward causal inference and personalized clinical applications.
Gao Y, Zhang C, Zhou Z-W, et al. Artificial intelligence in gut-brain axis research for Alzheimer’s disease: From associative insights toward causal inference and personalized interventions. Food & Medicine Homology Resources, 2026,https://doi.org/10.26599/FMHR.2026.9740006
Comments on this article